Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand J C
Department of Intensive Care, Hopital Bellevue, Saint-Etienne, France.
Lancet. 1991 Mar 30;337(8744):774-6. doi: 10.1016/0140-6736(91)91383-6.
4 patients had typical features of thrombotic thrombocytopenic purpura (TTP) after 3 to 8 weeks of ticlopidine therapy. In 2 ticlopidine was the only medication taken before TTP; in another, rechallenge with drugs other than ticlopidine that the patient had been taking did not produce relapse. In all patients the delay between start of ticlopidine and TTP was in the same range as the latent period before ticlopidine-induced neutropenia. No relapse occurred in the 4 to 43 months of follow-up in the 3 surviving patients.
4例患者在噻氯匹定治疗3至8周后出现血栓性血小板减少性紫癜(TTP)的典型特征。其中2例患者在发生TTP之前仅服用了噻氯匹定;另1例患者,重新使用其之前服用过的除噻氯匹定之外的药物并未导致复发。所有患者中,噻氯匹定开始使用至发生TTP的间隔时间与噻氯匹定诱导的中性粒细胞减少症之前的潜伏期处于同一范围。3例存活患者在4至43个月的随访中未出现复发。